1. A sunscreen composite particle comprising:
a) an UVA sunscreen suitable to undergo keto-enol tautomerization;
b) a condensation polymerizable resin; and
c) a solvent, the solvent being one in which the UVA sunscreen is soluble in and one having a dielectric constant from about 5.5 to about 9
wherein the particle imparts UVA and UVB sunscreen protection and is substantially free of supplied UVB sunscreen.
2. The sunscreen composite particle according to claim 1 wherein the UVA sunscreen can dissolve in the solvent to yield a solution which is at least about 15% by UVA sunscreen based on total weight of sunscreen and solvent.
3. The sunscreen composite particle according to claim 1 wherein the sunscreen is dibenzoyl methane or a derivative thereof.
4. The sunscreen composite particle according to claim 1 wherein the sunscreen has the formula:
where
R is H or a C1-3 alkyl;
R1 is a linear or branched C1-6 alkyl; and
each R2 is independently a C1-4 alkyl and i is zero or 1.
5. The sunscreen composite particle according to claim 1 wherein the sunscreen is 4-(1,1-dimethylethyl)-4\u2032-methoxydibenzoylmethane.
6. The sunscreen composite particle according to claim 1 wherein the resin is a polyester or polyamide, and the solvent is an imide or phthalimide.
7. The sunscreen composite particle according to claim 1 wherein the solvent has the formula:
where R7 is a C1-8 linear or branched alkyl and each R8 is independently H, OH, C1-3 alkoxy or a C1-5 alkyl group.
8. The sunscreen composite particle according to claim 1 wherein the solvent has the formula:
where R9 is a C1-6 linear or branched alkyl and each R10 is independently H or a C1-3 alkyl.
9. The sunscreen composite particle according to claim 8 wherein the solvent is butylisopropyl phthalimide.
10. A composition for providing UVA and UVB protection, the composition comprising a sunscreen composite particle comprising:
a) an UVA sunscreen suitable to undergo keto-enol tautomerization;
b) a condensation polymerizable resin; and
c) a solvent, the solvent being one in which the UVA sunscreen is soluble in and one having a dielectric constant from about 5.5 to about 9
wherein the particle imparts UVA and UVB sunscreen protection and is substantially free of supplied UVB sunscreen.
11. The composition according to claim 10 wherein the UVA sunscreen can dissolve in the solvent to yield a solution which is at least about 15% by UVA sunscreen based on total weight of sunscreen and solvent.
12. The composition according to claim 10 wherein the sunscreen is dibenzoyl methane or a derivative thereof.
13. The composition according to claim 10 wherein the sunscreen has the formula:
where
R is H or a C1-3 alkyl;
R1 is a linear or branched C1-6 alkyl; and
each R2 is independently a C1-4 alkyl and i is zero or 1.
where
R is H or a C1-3 alkyl;
R1 is a linear or branched C1-6 alkyl; and
R2 is a C1-4 alkyl.
14. The composition according to claim 10 wherein the sunscreen is 4-(1,1-dimethylethyl)-4\u2032-methoxydibenzoylmethane.
15. The composition according to claim 10 wherein the resin is a polyester or polyamide, and the solvent is an imide or phthalimide.
16. The composition according to claim 10 wherein the solvent has the formula:
where R7 is a C1-8 linear or branched alkyl and each R8 is independently H, OH, C1-3 alkoxy or a C1-5 alkyl group.
17. The composition according to claim 10 wherein the solvent has the formula:
where R9 is a C1-6 linear or branched alkyl and each R10 is independently H or a C1-3 alkyl.
18. The composition according to claim 17 wherein the solvent is butylisopropyl phthalimide.
19. The composition according to claim 16 wherein the solvent is a di- or tri-imide derived from the solvent represented by formula.
20. A method for obtaining UVA and UVB protection comprising the step of topically applying to skin the composition of claim 10.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1-118. (canceled)
119. A therapeutic administration system comprising:
a processor;
one or more instructions operable by the processor to obtain a flow-change-indicative measurement; and
one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement.
120. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to program an implantable device.
121. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to obtain turbulence-indicative auditory value as the flow-change-indicative measurement.
122. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to detect one or more conditions optically.
123. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to detect one or more force-change-indicative values.
124. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to decide upon at least one of the one or more clot-reducing agents in response to obtaining an anomalous value as the flow-change-indicative measurement.
125. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation.
126. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
127. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions responsive to a flow-force-responsive element.
128. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions responsive to an optical sensor.
129. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions responsive to an auditory sensor.
130. The therapeutic administration system of claim 119, further comprising:
a wireless-communication device.
131. The therapeutic administration system of claim 119, further comprising:
a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
132. The therapeutic administration system of claim 119, further comprising:
an implantable valve comprising at least one dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
133. The therapeutic administration system of claim 119, further comprising:
an implant-site-targeting dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
134-144. (canceled)
145. The therapeutic administration system of claim 119 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to signal at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation; and
one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
146. The therapeutic administration system of claim 145, further comprising:
an implantable valve comprising at least a first dispenser operable for dispensing at least a lytic material;
a second dispenser operable for targeting an implant site; and
a wireless-communication device operable for communicating a selection of the first dispenser or the second dispenser.
147. The therapeutic administration system of claim 119, further comprising:
an implantable valve comprising at least a first dispenser operable for dispensing at least a lytic material;
a second dispenser operable for targeting an implant site by dispensing at least the lytic material; and
a wireless-communication device operable for communicating a selection of the first dispenser or the second dispenser.
148-162. (canceled)
163-173. (canceled)
174-176. (canceled)
177. A therapeutic administration method comprising:
obtaining a flow-change-indicative measurement; and
signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement.
178. The therapeutic administration method of claim 177 in which the obtaining a flow-change-indicative measurement comprises:
programming an implantable device.
179. The therapeutic administration method of claim 177 in which the obtaining a flow-change-indicative measurement comprises:
obtaining a turbulence-indicative auditory value as the flow-change-indicative measurement.
180. The therapeutic administration method of claim 177 in which the obtaining a flow-change-indicative measurement comprises:
detecting one or more conditions optically.
181. The therapeutic administration method of claim 177 in which the obtaining a flow-change-indicative measurement comprises:
detecting one or more force-change-indicative values.
182. The therapeutic administration method of claim 177 in which the signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprises:
deciding upon at least one of the one or more clot-reducing agents in response to obtaining an anomalous value as the flow-change-indicative measurement.
183. The therapeutic administration method of claim 177 in which the signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprises:
signaling at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation.
184. The therapeutic administration method of claim 177 in which the signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprises:
causing one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
185-189. (canceled)
190. The therapeutic administration method of claim 177 in which the signaling a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprises:
deciding upon at least one of the one or more clot-reducing agents in response to obtaining an anomalous value as the flow-change-indicative measurement;
signaling at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation; and
causing one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
191-322. (canceled)
323. The therapeutic administration system of claim 119, further comprising:
a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
324. The therapeutic administration system of claim 119, further comprising:
an implant-site-targeting dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
325. The therapeutic administration system of claim 122 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to obtain a turbulence-indicative auditory value as the flow-change-indicative measurement.
326. The therapeutic administration system of claim 123 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
327. The therapeutic administration system of claim 123, further comprising:
a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
328. The therapeutic administration system of claim 125 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
329. The therapeutic administration system of claim 128, further comprising:
a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.
330. The therapeutic administration system of claim 128, further comprising:
a wireless-communication device.
331. The therapeutic administration system of claim 130 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to obtain a turbulence-indicative auditory value as the flow-change-indicative measurement.
332. The therapeutic administration system of claim 131 in which the one or more instructions operable by the processor to obtain a flow-change-indicative measurement comprise:
one or more instructions operable by the processor to obtain a turbulence-indicative auditory value as the flow-change-indicative measurement.
333. The therapeutic administration system of claim 131 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to signal at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation.
334. The therapeutic administration system of claim 132 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to signal at least an anticoagulant of the one or more clot-reducing agents in response to an apparent flow degradation.
335. The therapeutic administration system of claim 133 in which the one or more instructions operable by the processor to signal a decision whether to administer one or more clot-reducing agents at least partly based on the flow-change-indicative measurement comprise:
one or more instructions operable by the processor to cause one or more dispensations in response to an apparent problem in the flow-change-indicative measurement.
336. The therapeutic administration system of claim 133, further comprising:
a wireless-communication device.
337. The therapeutic administration system of claim 133, further comprising:
a thrombolytic-agent-containing dispenser responsive to the decision whether to administer the one or more clot-reducing agents.